

Catalan Study Group
for better detection
of AF in the SU

Stroke Risk Analysis (SRA)

A novel automatic system with a high detection rate of paroxysmal Atrial Fibrillation in the acute phase of Stroke

Results of a prospective, multicenter, intra-patient study with blinded assessors involving Stroke and TIA patients, admitted consecutively in the Stroke Unit, comparing the new diagnostic technology SRA with standard Continuous ECG Monitoring (CEM)

Dávalos A¹, Cardona P², Gomis M¹, Martí-Fàbregas J³, Pagola J⁴, Purroy F⁵, Rodríguez-Campello A⁶, Roquer J⁶, Serena J⁷, Mont L⁸, Abilleira S⁹, Molina C⁴, Neeter R¹⁰


DESIGN

- Prospective, multicenter, intra-patient, daily practice, semi-blinded study.
- 462 consecutive Stroke and TIA patients admitted in the Stroke Unit of 7 University Hospitals in Catalonia.
- Neither history of AF, nor AF in the admission ECG.
- ECG monitoring with (A) standard CEM and (B) 5-lead, 2-channel Holter with SRA, the automated, dedicated software to identify AF and Risk of AF.


RESULTS

- SRA detected 78 patients with high probability of AF.
- Review of independent cardiologist limited the validated cases to 45.
- SRA detected 2,1 times more validated AF cases than standard CEM.
- SRA detected AF 56 hours earlier (= 2,7 times faster) than standard CEM.
- The negative predictive value of SRA in the 1st Cycle is 96%.
- Only 5% of patients judge the Holter as uncomfortable.


Patients detected with pxAF



Yield of pxAF during monitoring in SU



Time to detect an active AF episode



CENTERS

1. Hospital Germans Trias i Pujol
2. Hospital de Bellvitge
3. Hospital Sant Pau
4. Hospital Vall d'Hebron
5. Hospital Arnau i Vilanova de Lleida
6. Hospital del Mar
7. Hospital Josep Trueta de Girona
8. Hospital Clinic
9. Government of Catalonia, Stroke Programme
10. Evina Health Solutions

CONCLUSIONS

SRA plus cardiological validation detects 2 times more and 3 times faster AF patients than standard CEM. The negative predictive value of SRA in the 1st Cycle and the comfort of the Holter are additional benefits. The important advantages and the lack of disadvantages make SRA a superior alternative to CEM. The low cost and short response time of SRA complete the beneficial profile.

apoplex[®] SRA is a product
of Apoplex Medical Technologies

EVINA[®] SRA is distributed
in Spain and Spanish
speaking countries by Evina Spain